We recently published an updated study that looked at where Canadian generic prices are, relative to international levels, and I can say there is some good news on that front, in that the efforts of the pan-Canadian Pharmaceutical Alliance have closed some of those gaps.
The report that we do is fairly comprehensive, so it doesn't pick and choose those examples, because there are examples of both extremes.
I just want to caution that when we looked at New Zealand and compared prices in New Zealand with prices in Canada, we found that there was a much smaller sample of drugs with which we could compare. That suggests that there is potentially a lower supply of generic products, so there is potentially a risk that adopting a certain model could result in less choice.
What the impact of that is for therapies is a different question, but it is certainly something that needs to be looked at.